Table 2.

Capromorelin Study of Older Subjects at Risk of Functional Decline

	Change Versus Baseline at 12 Months
	Placebo (kg)	Capromorelin (kg)
FFM	0.6 + 1.4	1.6 + 3.2	p = .02
Body weight	−0.1 + 2.2	1.2 + 5.2	p = .06

Notes: IGF-I levels in capromerlin- versus placebo-treated subjects increased by ~1.5-fold p = .001. FFM = fat-free mass; IGF-1 = insulin-like growth factor